lovastatin has been researched along with Cognitive Decline in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ackerson, JD; Acosta, MT; Barton, B; Cantor, A; Coghill, D; Cutter, G; Fisher, MJ; Gioia, GA; Gutmann, DH; Haebich, KM; Hearps, SJC; Klesse, L; Korf, B; North, KN; Packer, RJ; Paltin, I; Payne, JM; Rey-Casserly, C; Rosser, T; Schorry, EK; Tonsgard, JH; Ullrich, NJ; Viskochil, D; Walsh, KS | 1 |
| Cutter, G; North, K; Packer, R; Payne, JM; Rey-Casserly, C; Ullrich, NJ; Walsh, KS | 1 |
| Chu, H; Dong, Y; Jiang, Q; Tian, Y; Wang, C; Xu, Y | 1 |
2 trial(s) available for lovastatin and Cognitive Decline
| Article | Year |
|---|---|
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.
Topics: Adolescent; Biomarkers; Child; Clinical Trials as Topic; Cognitive Dysfunction; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Neurofibromatosis 1; Outcome Assessment, Health Care; Reproducibility of Results | 2019 |
Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1.
Topics: Adolescent; Child; Cognitive Dysfunction; Feasibility Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Maze Learning; Neurofibromatosis 1; Neuropsychological Tests; Spatial Learning | 2020 |
1 other study(ies) available for lovastatin and Cognitive Decline
| Article | Year |
|---|---|
Lovastatin attenuates sevoflurane-induced cognitive disorder in aged rats via reducing Aβ accumulation.
Topics: Aging; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Cognition; Cognitive Dysfunction; Hippocampus; Lovastatin; Mice; Plaque, Amyloid; Rats, Sprague-Dawley; Sevoflurane | 2021 |